HER2的发现 1979年,Weinberg等人在大鼠胶质母细胞瘤中发现了一种特殊的癌基因并命名为“neu”。随后的1985年到1987年期间,有三个研究团队几乎同时测定出人类c-neu同源基因——HER2(亦称c-erbB-2)。HER2蛋白的配体结合域呈开放构象,通过形成...
[6]Rüschoff J, Friedrich M, Nagelmeier I, et al. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status....
Hanna W, Nofech-Mozes S, Kahn HJ (2007) Intratumoral heterogeneity of HER2/neu in breast cancer—a rare event. Breast J 13(2):122–129Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer - a rare event. Breast J. 2007; 13 :122–129. doi: ...
Introduction: Breast cancer is among the most prevalent cancers in women globally, with patients' survival adversely impacted by Ki67 expression and triple-negative phenotypes. In this study, we examined the relations...
10.Yael Bar,et al.Dynamic HER2-low status among patients with triple negative breast cancer(TNBC):The impact of repeat biopsies.2023 ASCO:Abstract 1005. 11.Tarantino P,et al.ESMO expert consensus statements(ECS)on the definition,diagnosis,and management of HER2-low breast cancer.Ann Oncol.2023...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
In the BEVERLY-1 (UCBG-0802) trial we aimed to assess the addition of bevacizumab to neoadjuvant and adjuvant chemotherapy in the treatment of patients with HER2-negative inflammatory breast cancer. Methods: We did this phase 2, ... Franois Bertucci,M Fekih,A Autret,... - 《Lancet Oncology...
phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAI...
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831 (1998). CAS Google Scholar Pegram, M. et al. Inhibitory effects of combinations of HER-2/...
The Her2/Neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between...